Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Overview
Phosphorylethanolamine (O-Phosphorylethanolamine) is a phosphomonoester metabolite of the phospholipid metabolism. Phosphorylethanolamine is a precursor of phospholipid synthesis and a product of phospholipid breakdown. Phosphomonoesters are present at much higher levels in the brain than in other organs. In developing the brain, phosphomonoesters are normally elevated during the period of neuritic proliferation. This also coincides with the occurrence of normal programmed cell death and synaptic pruning in developing the brain. These findings are consistent with the role of phosphomonoesters in membrane biosynthesis. Phosphorylethanolamine shows a strong structural similarity to the inhibitory neurotransmitter, GABA, and the GABAB receptor partial agonist, 3-amino-propylphosphonic acid. Phosphorylethanolamine is a phosphomonoester which is decreased in post-mortem Alzheimer's disease (AD) brain.
Chemical Properties
| Molecular Formula | C2H8NO4P |
| Molecular Weight | 141.06 |
| CAS Numbers | 1071-23-4 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | NCCOP(O)(O)=O |
Storage and Handling
0C Short Term, -20C Long Term
References
Klunk W E, et al. Inactivity of phosphoethanolamine, an endogenous GABA analog decreased in Alzheimer's disease, at GABA binding sites[J]. Life Sciences, 1995, 56[26] 2377.